LEADER 01416nam  2200385Ia 450 
001 9910698880003321
005 20090507132812.0
035   $a(CKB)5470000002397063
035   $a(OCoLC)320456955
035   $a(EXLCZ)995470000002397063
100   $a20090507d2007      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $emanufacturing biological intermediates and biological drug substances using spore-forming microorganisms
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2007]
215   $aii, 14 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 7, 2009).
300   $a"September 2007".
517   $aGuidance for industry 
606   $aIntermediates (Chemistry)
606   $aSporeforming bacteria$zUnited States
606   $aPharmaceutical biotechnology$zUnited States
615  0$aIntermediates (Chemistry)
615  0$aSporeforming bacteria
615  0$aPharmaceutical biotechnology
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698880003321
996   $aGuidance for industry$93434577
997   $aUNINA